- Home
- DRMA vs UGRO Comparison
DRMA vs UGRO Comparison
Compare DRMA & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- UGRO
- Stock Information
- Founded
- DRMA 2014
- UGRO 2014
- Country
- DRMA United States
- UGRO United States
- Employees
- DRMA N/A
- UGRO N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- UGRO Industrial Specialties
- Sector
- DRMA Health Care
- UGRO Consumer Discretionary
- Exchange
- DRMA Nasdaq
- UGRO Nasdaq
- Market Cap
- DRMA 4.5M
- UGRO 3.8M
- IPO Year
- DRMA 2021
- UGRO N/A
- Fundamental
- Price
- DRMA $0.71
- UGRO $0.32
- Analyst Decision
- DRMA Strong Buy
- UGRO Strong Buy
- Analyst Count
- DRMA 1
- UGRO 1
- Target Price
- DRMA $3.00
- UGRO $3.00
- AVG Volume (30 Days)
- DRMA 118.5K
- UGRO 538.3K
- Earning Date
- DRMA 08-06-2025
- UGRO 07-22-2025
- Dividend Yield
- DRMA N/A
- UGRO N/A
- EPS Growth
- DRMA N/A
- UGRO N/A
- EPS
- DRMA N/A
- UGRO N/A
- Revenue
- DRMA N/A
- UGRO $59,985,138.00
- Revenue This Year
- DRMA N/A
- UGRO N/A
- Revenue Next Year
- DRMA N/A
- UGRO $31.25
- P/E Ratio
- DRMA N/A
- UGRO N/A
- Revenue Growth
- DRMA N/A
- UGRO N/A
- 52 Week Low
- DRMA $0.57
- UGRO $0.26
- 52 Week High
- DRMA $5.00
- UGRO $1.92
- Technical
- Relative Strength Index (RSI)
- DRMA 53.74
- UGRO 55.26
- Support Level
- DRMA $0.61
- UGRO $0.29
- Resistance Level
- DRMA $0.74
- UGRO $0.34
- Average True Range (ATR)
- DRMA 0.06
- UGRO 0.04
- MACD
- DRMA 0.01
- UGRO 0.01
- Stochastic Oscillator
- DRMA 67.43
- UGRO 49.04
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.